SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-109069
Filing Date
2024-09-24
Accepted
2024-09-24 16:05:07
Documents
11
Period of Report
2024-09-24
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20240924.htm   iXBRL 8-K 52543
  Complete submission text file 0000950170-24-109069.txt   175980

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20240924.xsd EX-101.SCH 30854
13 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20240924_htm.xml XML 4708
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 241320217
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)